In immune-induced liver damage the reactive metabolites may covalently bind or alter liver proteins such as cytochrome P450 enzymes, which leads to activation of the immune system. Ticlopidine is an inhibitor of CYP2C19 human liver cytochrome. We attempted to analyse the role of cytochrome CYP2C19 genetic polymorphism in the development of ticlopidine-induced cholestatic hepatitis and relate it with the specific immune reactivity to ticlopidine, different cytokine profiles and induction of necrosis and apoptosis within the liver tissue. Three patients with cholestatic hepatitis with ticlopidinerelated liver injury, 3 patients with obstructive jaundice due to choledocholithiasis, 3 patients treated with ticlopidine without liver damage and 10 healthy individuals were studied. Genotyping for the following genotypes CYP2C19 (CYP2CI9*1-3) were tested after polymerase chain reaction (PCR) by restriction fragment length polymorphism (RFLP) with Sma I and BamH I enzymes. The T cell reactivity to ticlopidine was analysed by T cell proliferation assay in PBMC against ticlopidine, tetanus toxoid antigen and phytohemagglutinin on days 0, 90, 150 and 210 after therapy withdrawal. The serum levels of INF-y, IL-2, IL-4, IL-I0, TNF-a, sFas and sFasL were measured by ELISA at the same time points. Apoptosis was analysed by TUNEL assay. All patients with cholestatic hepatitis had "slow metabolizers" genotypes in contrast to other groups. The T cell reactivity to ticlopidine was present only in all the cholestatic hepatitis patients together with substantial decrease in levels of INF-y, IL-2 and TNF-a during all of the follow-up period. Cholestatic hepatitis patients had high apoptotic index in TUNEL assay. The genetic polymorphism of the cytochrome CYP2C19 gene is directly responsible for the susceptibility to the ticlopidine-induced liver damage. Thl type of immune reactivity plays the key role in the pathogenesis of drug-induced hepatotoxicity.
It is considered that more than 1000 drugs cause hepatotoxicity.
Six mechanisms ofliver injury have been described in DILl (2) . The variable intracellular organelles are affected. Firstly, the changes in hepatocytes membrane were associated with intracellular calcium metabolism interference and further cell lysis. Secondly, the disruption of actin filaments leads to the impairment of transport pumps and consequently influences bilirubin transport mainly in cholestatic damage. Thirdly, the drug's covalent binding into cytochrome P450 enzyme system can directly have an effect on enzyme system functions or can act indirectly as neoantigens by triggering the immune system. Fourthly, this activation of the immune system is often associated with inducing apoptotic pathways via tumour necrosis factor (TNF) receptor or Fas-induced apoptosis. Fifthly, certain drugs are able to directly inhibit mitochondrial functions and therefore decrease adenosine triphosphate (ATP) production with further accumulation of lactate or/ and reactive oxygen compounds. Finally, some toxic drug metabolites might be associated with the direct damage of bile duct epithelium.
Additionally, genetic factors linked with drug metabolism, detoxification and its transport, as well as genetic polymorphism of these factors and aspects influencing cell injury and repair, are directly involved in DILL The environmental factors (i.e. concomitant drugs or alcohol), drug chemical properties, age, sex and underlaying disease create the complex of interactions for hepatotoxicity risk (3) (4) .
Ticlopidine is an antiplatelet agent that selectively and irreversibly inhibits adenosine diphosphate (ADP) and its receptor on the platelet surface by binding onto it. The ADP-dependent activation of the platelet glycoprotein lIb/IlIa receptor is blocked and the platelet aggregation is abrogated. The results of Canadian American Ticlopidine Study (CATS) showed that 4.4% of patients participating in this trial developed abnormal liver function tests (LFTs). In the majority of them, this finding was associated with the elevation of alkaline phosphatase (ALP) levels, in comparison to jaundice, which was relatively rare (5) . In contrast, other side effects as neutropenia occurred only in about 1% of patients.
Ticlopidine [5-(2-chlorphenyl) methyl--4,5,6,7tetrahydrothieno [3 ,2-c] pyridine] acts as a selective mechanism-based inhibitor of cytochrome 2C 19 (6) and leads to its direct inactivation via reactive intermediate, an electrophilic thiophene-S-oxide (7) . The main metabolic pathway in the liver is through N-dealkylation, N-oxidation and oxidation of the thiophene ring (8) . The studies of ticlopidine pharmacokinetics have established that the median peak concentrations in plasma after regular administration of 250 mg dose every 12 hours were 0.99 mg/l (range 0.22-2.12 mg/ml) (9) . The interaction of these active metabolites with cytochrome P450 enzymes in relation to their genetic polymorphism could be in charge of slow metabolism of the drug and hence connected with the development of neoantigens triggering specific immune response (10) (11) . The specific immune reactivity against these neoantigens is associated with DILl (12) . To answer the question, what type of immune reaction is associated with ticlopidineinduced cholestatic hepatitis and if polymorphism within genotype of human liver cytochrome CYP2C 19 could be related to the development of liver injury due to ticlopidine treatment, we studied the dynamic changes of T cell reactivity to ticlopidine, the changes in serum cytokine profiles and apoptosis markers, and finally we evaluated CYP2C 19 genotype among patients with ticlopidineinduced liver damage and three control groups.
Drug-induced liver injury (DILl) is a common cause of liver damage. It manifests as acute or chronic liver disease, from practically minimal elevation of liver function tests to life threatening acute liver failure. The drug-induced hepatic injury is extremely variable and results in a disease with hepatic, cholestatic or mixed clinical presentation (1). The withdrawal of the drug resolves the disease. It is considered that more than 1000 drugs cause hepatotoxicity.
Six mechanisms of liver injury have been described in DILl (2) . The variable intracellular organelles are affected. Firstly, the changes in hepatocytes membrane were associated with intracellular calcium metabolism interference and further cell lysis. Secondly, the disruption of actin filaments leads to the impairment of transport pumps and consequently influences bilirubin transport mainly in cholestatic damage. Thirdly, the drug's covalent binding into cytochrome P450 enzyme system can directly have an effect on enzyme system functions or can act indirectly as neoantigens by triggering the immune system.
Fourthly, this activation of the immune system is often associated with inducing apoptotic pathways via tumour necrosis factor (TNF) receptor or Fasinduced apoptosis. Fifthly, certain drugs are able to directly inhibit mitochondrial functions and therefore decrease adenosine triphosphate (ATP) production with further accumulation of lactate or/ and reactive oxygen compounds. Finally, some toxic drug metabolites might be associated with the direct damage of bile duct epithelium.
Additionally, genetic factors linked with drug metabolism, detoxification and its transport, as well as genetic polymorphism of these factors and aspects influencing cell injury and repair, are directly involved in DILl. The environmental factors (i.e. concomitant drugs or alcohol), drug chemical properties, age, sex and underlaying disease create the complex of interactions for hepatotoxicity risk (3) (4) .
Ticlopidine is an antiplatelet agent that selectively and irreversibly inhibits adenosine diphosphate (ADP) and its receptor on the platelet surface by binding onto it. The ADP-dependent activation of the platelet glycoprotein lIb/IlIa receptor is blocked and the platelet aggregation is abrogated. The results of Canadian American Ticlopidine Study (CATS) showed that 4.4% ofpatients participating in this trial developed abnormal liver function tests (LFTs). In the majority of them, this finding was associated with the elevation of alkaline phosphatase (ALP) levels, in comparison to jaundice, which was relatively rare (5) . In contrast, other side effects as neutropenia occurred only in about I% of patients.
Ticlopidine [5-(2-chlorphenyl)methyl-4,5,6,7tetrahydrothieno[3,2-c]pyridine] acts as a selective mechanism-based inhibitor of cytochrome 2C19 (6) and leads to its direct inactivation via reactive intermediate, an electrophilic thiophene-S-oxide (7) . The main metabolic pathway in the liver is through Ndealkylation,N-oxidationand oxidationof the thiophene ring (8) . The studies of ticlopidine pharmacokinetics have established that the median peak concentrations in plasma after regular administration of 250 mg dose every 12 hours were 0.99 mg/I (range 0.22-2.12 mg/ ml) (9) . The interaction ofthese active metabolites with cytochrome P450 enzymes in relation to their genetic polymorphism could be in charge of slow metabolism ofthe drug and hence connected with the development of neoantigens triggering specific immune response (10) (11) . The specific immune reactivity against these neoantigens is associated with DILl (12) . To answer the question, what type of immune reaction is associated with ticlopidine-induced cholestatic hepatitis and if polymorphism within genotype of human liver cytochrome CYP2C 19 could be related to the development of liver injury due to ticlopidine treatment, we studied the dynamic changes of T cell reactivity to ticlopidine, the changes in serum cytokine profiles and apoptosis markers, and finally we evaluated CYP2C 19 genotype among patients with ticlopidine-induced liver damage and three control groups.
MATERIALS AND METHODS

Patients
Three patients with cholestatic hepatitis related to ticlopidine treatment (CH), 3 patients with obstructive jaundice due to choledocholithiasis (OBS), 10 healthy individuals (HEA) and 3 patients treated with ticlopidine without liver damage (TT) participated in the present study. The diagnosis of ticlopidine-induced cholestatic hepatitis was established in three patients who developed prolonged cholestasis 2-12 weeks after receiving ticlopidine 250 mg twice per day following percutaneous coronary angioplasty (PTCA). Liver damage developed 2 weeks after discontinuation of the drug in one of the studied patients. No dilatation or pathological changes of intrahepatic or extrahepatic bile ducts were diagnosed by ultrasound and ERCP. Other causes of liver injury were excluded. All autoantibodies associated with autoimmune liver diseases were negative in these patients. The center-acinar cholestasis, infiltration of bile ducts with lymphocytes and eosinophils, focal piecemeal necrosis, infiltration of the portal tracts with lymphocytes and eosinophils were consistent with the diagnosis. The cholestatic hepatitis patients were evaluated according to Maria's scale score for the diagnosis of drug-induced hepatitis (13) . The results of biochemical and haematological markers of liver damage and cholestasis of these four groups are shown in Table I . The group of patients with cholestatic liver damage due to ticlopidine consists of three males with the mean age 54.7 ± 19.5 years (range 41-77 years). Three patients with obstructive jaundice were males with mean age 58.0 ± 12.5 years (range 48-72 years). In the group of healthy volunteers were five males and five females with the mean age 42 ± 6.2 years (range 28-47 years). The group of patients treated with ticlopidne (250 mg twice' per day for a period range from 18 to 32 weeks) without any liver damage consists of three individuals (3 males) with the mean age 65.3 ± 9.6 years (range 55-74 years).
Materials
Serum and peripheral blood were obtained from each patient participating in the study. All three patients with the ticlopidine-related liver damage underwent a diagnostic liver biopsy. The serum samples from the patients with ticlopidine induced cholestatic hepatitis were collected at different time-points after the drug withdrawal -on days 0, 90, 150 and 210. The peripheral blood mononuclear cells (PBMC) were isolated from whole heparinised blood by density gradient centrifugation using Lymphoprep (Nycomed, Oslo, Norway), washed three times with RPMI 1640 supplemented with 25 mmol/I Hepes buffer solution, 2 mmol/I L-glutamine, 100U/ml of penicillin, 100 mg/ml streptomycin (all from Gibco Invitrogen Corp., Paisley, UK) and 6 mmol/I NaOH (Sigma Aldrich, Poole, Dorset, UK). After the final wash the cells were re-suspended in RPMI 1640 supplemented with 10% (vol/vol) heat inactivated foetal calf serum (FCS) (Gibco Invitrogen Corp., Paisley, UK). The PBMC were collected from all 19 studied participants and from three patients with cholestatic hepatitis on the day of the drug discontinuation and at the same follow-up time-points as serum. Routine biochemical and haematological parameters as serum concentrations of bilirubin, alanin aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (y-GT), lipids (cholesterol and triglycerides) and proportion of eosinophils in peripheral blood were evaluated on the same days.
T-cellproliferation assay
The T cell proliferative response to ticlopidine (Sigma Aldrich, Poole, Dorset, UK) in the therapeutic concentration was analysed as described previously in all twelve patients. Briefly, isolated PBMC were cultured in 96-well microtiter plates (Nunclon, Gibco BRL, Glasgow, Scotland) at 2x10 5 cells/well in buffered RPMI 1640, supplemented with heatinactivated foetal calf serum (FCS) at 37°C with 5% CO 2 for 6 days. Ticlopidine at final concentrations 0.25 and 0.5 and I ug/rnl was used for specific cell stimulation. Tetanus toxoid (Connaught International Laboratories, Ontario, Canada, final concentration 0.5 ug/ml) to evaluate antigen specific immune response and phytohemagglutinin (PHA) (Sigma Aldrich, Poole, Dorset, UK, final concentration I ug/rnl) to test non-antigenic stimulation were included as positive controls in all assays. All samples were tested in the presence or absence of ticlopidine and antigens in triplicate. The proliferative response was evaluated by BrdU colorimetric cell proliferation ELISA (Roche Applied Science, Mannheim, Germany) according to provided manufacturer's instructions (14) . The absorbance of samples was measured by an ELISA reader at 370 nm to reference wavelength 492 nm. The stimulation index (SI) was calculated from the mean of absorbance found in the test wells with PBMC plus ticlopidine or an antigen divided by that found in the control wells with PBMC without any antigen or stimulus. Ticlopidine was tested also in the presence of PBMC derived from 10 healthy individuals. The cut-off for a significant proliferative response was defined as a stimulation index (SI) greater than 3.0, which was greater than the mean of stimulation index in the presence of ticlopidine plus 3 standard deviations in all negative controls.
ELISAfor serum cytokines and soluble markers ofFasinduced apoptosis
Serum levels of cytokines interferon-gamma (IFN-y), interleukin-2 (IL-2), interleukin-4 (ILA), interieukin-IO (IL-1O) and tumour necrosis factor-alpha (TNF-a) were measured by ELISA (BioSource International, Camarillo, CA, USA) according to the manufacturer's instructions. The serum concentrations ofFas-induced apoptosis soluble markers sFas (CD95+) and sFas-Ligand (CDI78+) were determined by ELISA (R&D Systems Inc., Minneapolis, MN, USA). The concentrations were measured in all 19 studied individuals and in 3 patients with cholestatic hepatitis on days 0, 90, 150 and 210 after the end of the therapy with ticlopidine to establish the dynamic changes in cytokine profiles.
Immunohistochemistry for CD4+, CD8+ and CD95+ cells
The distribution of T lymphocytes and CD95+ cells in the liver was visualised by immunostaining in formalinfixed, paraffin embedded liver specimens obtained from liver biopsy of patients with ticlopidine-related cholestatic hepatitis. The liver tissue from healthy liver graft donor was used as a negative control. For T cell antigens retrieval the liver sections were microwaved in antigen retrieval high pH solution (S3307, Dako, Ely, UK), for CD4+ antigen, in citrate buffer (pH=6.0) for CD8+ antigen as well as in citrate buffer (pH=6.0) for CD95+ antigen. The specimens were incubated with monoclonal antibodies to human CD4 (clone IF6, Novocastra, Newcastle, UK), CD8 molecules (clone C8/144B, Dako, Ely, UK) and to human CD95 (clone GM30, Novocastra, Newcastle, UK). The detection was with a sensitive immunoperoxidase kit (EnVision anti-mouse HRP system, Dako) and diaminobenenzidine as a substrate. The sections were counter-stained with haematoxylin. The proportion of CD4+ and CD8+ cells in the portal tracts and the intralobular areas was compared in 3-5 equivalent fields under 400x magnifications in microscope (Standard 20, Zeiss, lena, Germany). The number of CD95 positive cells was evaluated by the same method.
TdT-mediated dUTP nick end labelling (TUNEL) assay
Formalin-fixed paraffin-embedded slides of liver tissues from all 3 patients with cholestatic hepatitis due to ticlopidine have been analysed by enzymatic in situ labelling of DNA strand breaks which occurs early during apoptosis (15) . The liver tissue from healthy liver graft donor was used as a negative control. The same tissue, treated with DNase I (Roche Diagnostics, Penzberg, Germany) prior incubation to induce DNA strand brakes, served as a positive control. The liver specimens were pretreated by microwave irradiation in 0.1 M citrate buffer (pH 6.0). Tissue was incubated with TUNEL reaction mixture (Roche Diagnostics, Penzberg, Germany) for 60 minutes at 37°C. To visualize apoptotic cells by light microscopy, the incubation with TUNEL-POD (Roche Diagnostics, Penzberg, Germany) for 30 minutes at 37°C and substrate solution of diaminobenzidine (DAB) (Roche Diagnostics, Penzberg, Germany) was performed. The sections were counter-stained with haematoxylin. The proportion of apoptotic cells in liver specimens of patients with ticlopidine-induced cholestatic hepatitis was compared with the staining in the healthy liver tissue and positive control tissue treated with DNase I.
Allele and genotype testing o!CYP2C19
In all 19 participants of the study allele and genotype testing of CYP2C 19 were performed. DNA was extracted from leukocytes by Miller's method (16) . Genotyping for the following genotypes CYP2C 19*I, CYP2C 19*2 and CYP2C19*3 were tested by polymerase chain reaction combined with restriction fragment length polymorphism method (PCR-RFLP) as was published by Sviri et al. (17) . Briefly, the forward primer: 5'-AATTACAACCAGAGCTTGGC-3' and reverse primer: 5'-TATCACTTTCCATAAAAGCAAG-3' were used for PCR amplification of CYP2C19*2 (G681A). For the analysis of CYP2C19*3 allele (G636A), the PCR amplification was performed with forward primer: 5'-TAT TAT TAT CTG TTA ACT AATATGA-3' and reverse primer: 5'-ACTTCAGGGCTTGGTCAATA-3'. Restriction enzymes Sma I (Promega Corp., USA) and BamH I (Promega Corp., USA) were used for digestion of the PCR products of CYP2C19*2 and CYP2C19*3. The PCR products were separated after digestion on a 6% polyacrylamide gel. Since the restriction site is not present in the polymorphism alleles CYP2C 19*2 and CYP2CI9*3, the PCR products are not digested by restriction enzymes. In the CYP2C 19*I allele the restriction enzymes Sma I and BamH I divide DNA fragment 169 bp into 2 fragments: 120 bp and 49 bp and splice DNA fragment 329 bp to two fragments: 233 bp and 96 bp, respectively. Positive and negative controls were always included in each PCR and restriction assays. The samples containing the mutant alleles were retested.
Statistical analysis
The differences in results among four groups and four different time-points were compared using Mann Whitney U non-parametric test. The correlation between variables was assessed using the Spearman rank order correlation coefficient. Statistical analysis was performed using SPSS (SPSS Inc., Chicago, IL, USA) statistical package.
RESULTS
The biochemical markers ofliver damage
The concentrations of liver function tests, cholesterol, triglycerides and the proportion of eosinophils within peripheral blood were evaluated during withdrawal period (Table II) . ALT and AST levels were normalised on days 90 and 75, respectively. The serum bilirubin, GMT and ALP levels were within normal range on days 150, 150 and 210 respectively. The proportion of eosinophils, the serum levels of cholesterol and triglycerides were correlated with the decrease of bilirubin and cholestatic enzymes levels (days 150, 150 and 210 respectively). The restoration of liver damage after ticlopidine withdrawal was indicated firstly by normalisation of aminotransferases followed by decrease in bilirubin and cholestatic enzyme levels.
T cell proliferation
The T cell reactivity to ticlopidine was present in all patients with cholestatic hepatitis during the entire follow-up period (Fig.lA) . The strongest T cell responses to ticlopidine were found immediately after the treatment cessation. However, during the withdrawal period the ticlopidine-specific T cell reactivity steadily decreased, the T cell responses to ticlopidine were still positive on day 210 after ticlopidine treatment ending at the same time-point when liver function tests were already normalised. The stimulation of peripheral blood mononuclear cells with different ticlopidine concentrations established that the ticlopidine concentration of 0.5 mg/ml was the stronger stimulus in comparison to other two used concentrations (0.25 and 1 mg/ml respectively). None of the patients from the other three groups responded to ticlopidine in different concentrations. This dissimilarity in the ticlopidinespecific T cell reactivity between patients with cholestatic hepatitis and patients from other studied groups was statistically significant (p=O.O 16). There were no differences in T cell reactivity to tetanus toxoid antigen and phytohemagglutinin among all four studied groups (Fig. 1B) .
Serum interferon-gamma (IFN-y) cytokine levels
Serum concentration of IFN-y gradually decreased during follow-up period after ticlopidine withdrawal. The highest concentrations in all three cholestatic hepatitis patients were found immediately after ticlopidine cessation (mean±SD) (47.2 ± 9.9 pg/ml, range 56.9 -37.0 pg/ml). From follow-up day 150 serum levels ofIFN-y did not differ among patients with cholestatic hepatitis and other studied groups (Fig. 2) .
Interleukin-Z (IL-2)
The same pattern ofthe changes as in IFN-y serum levels was found when serum concentrations of IL-2 were studied. The decrease of IL-2 serum levels was sharper in comparison to IFN-y and reached the concentrations found among other groups on day 210 after treatment withdrawal (Fig. 2) .
Interleukin-t (IL-4)
The serum concentrations of IL-4 were slightly raised among patients with ticlopidine-related cholestatic hepatitis immediately after drug stopping and on day 90 after withdrawal in comparison to three other studied groups (Fig. 2) .
lnterleukin-l O(IL-IO)
Serum IL-I0 levels were to some extent decreased at the start of drug cessation period (day oand day 90) when compared to healthy volunteers and ticlopidine treated individuals without liver damage groups. The end of withdrawal period (day 210) was characterized by slight increase of serum IL-I0 concentrations and almost reached the levels found among ticlopidine treated individuals (49.4 ± 3.2 pg/ml vs. 49.9 ± 3.0 pg/ml).
Tumour necrosis factor-alpha (TNF-a)
There were significant changes in serum concentrations of TNF-a among cholestatic hepatitis patients during the withdrawal period. However, TNF-a serum levels were progressively decreasing in the follow-up period in patients with cholestatic hepatitis, they did not reached the serum levels found among healthy controls or ticlopidinetreated individuals without liver damage (Fig. 2) . TNF-a levels on follow-up day 210 were twofold higher in cholestatic hepatitis patients than in healthy volunteers and ticlopidine-treated patients without liver injury (62.9 ± 4.3 pg/ml vs. 6.7 ± 0.8 pg/ml and 7.1 ± 1.1 pg/ml respectively). The serum concentrations ofTNF-a were also raised in patients with cholestasis due to choledocholithiasis, when compared to healthy controls and/or ticlopidine treated.
Serum levels of Fas-induced apoptosis soluble factors
The serum concentrations of sFas were significantly increased in patients with cholestatic hepatitis at the ending of ticlopidine therapy in comparison to healthy volunteer levels (1898.7 ± 125.1 pg/ml vs. 59.7 ± 7.4 pg/rnl, p=0.008). The levels of sFas sharply decreased during followup period from 1898.7 ± 125.1 pg/ml on day of cessation to 133 ± 13.7 pg/ml on day 210 (Fig.  3A) . The comparison of the sFas serum levels at the end of the withdrawal period in cholestatic hepatitis patients with the concentrations among healthy individuals and ticlopidine treated patients without liver damage indicate that these levels are about two-fold increased among patients with cholestatic hepatitis at this time-point. The serum concentrations of soluble Fas were also elevated in patients with cholestasis due to choledocholithiasis, but these levels were not higher than sFas serum concentrations in cholestatic hepatitis patients on the day of treatment cessation and on day 90 after therapy ending (813.3 ± 13.9 pg/ml vs. 1898.7 ± 125.1 pg/ml and 1250 ± 74.5 pg/ml respectively).
The similar pattern of dynamic changes in serum concentrations as for sFas was observed when sFasL serum levels were studied (Fig. 4) .
Proportions of CD4+, CD8+ and CD95+ cells within the liver by immunohistochemistry
The number of CD8+ cells within the portal tracts and the intralobular space was significantly increased in patients with ticlopidine-induced cholestatic hepatitis in contrast to healthy liver tissue (portal tracts: 15.8 ± 8.0 cells per tract vs. 4.25 ± 0.65 cells per tract, p=O.OII; intralobular: 6.9 ± 4.3 cells per field vs. 0.25 ± 0.12 cells per field, p=0.006). The proportion of CD4+ lymphocytes in portal tracts was considerably higher in patients with cholestatic hepatitis than in healthy liver tissue (7.4 ± 3.2 cells per tract vs. 2.2 ± 2.8 cells per tract). The number of CD95+ hepatocytes was significantly higher among cholestatic hepatitis sufferers in comparison to the healthy liver (19.4 ± 2.9 cells per field vs. 3.4 ± 0.5 cells per field, p=0.017).
Results ofTUNEL assay in the liver tissue
The number ofDNA strand brakes within the liver tissue was higher among patients with ticlopidineinduced hepatitis than within the liver from a healthy liver donor (6.9 ± 1.4 vs. 0.25 ± 0.125 DNA strand brakes per field). The liver treated with DNase I prior TUNEL assay showed an increase in the number of DNA stand brakes (18.2 ± 3.6 DNA strand brakes per filed).
Results of allele and genotype testing of CYP2C19
There were 8 subjects with CYP2C 19*1/ CYP2C 19*1 genotype (1/1) (2 patients with obstructive jaundice, 1 ticlopidine treated individual without liver damage and 5 healthy volunteers). Heterozygous genotype CYP2C 19*1/CYP2C 19*2 (1/2) was diagnosed in 5 healthy individuals.
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Genotype CYP2C19C*1/CYP2CI9*3 (1/3) was found in 1 patient with obstructive jaundice and in 2 ticlopidine-treated individuals without liver injury. In contrast, the polymorphism alleles were present in genotypes of all 3 patients with cho1estatic hepatitis due to ticlopidine treatment. Two of them were homozygous, having a CYP2C19*21 CYP2C19*2 genotype (2/2). One patient in this group was heterozygous with both polymorphism alleles genotype CYP2C19*2/CYP2C19*3 (2/3). None of the studied individuals had homozygous genotype: CYP2C19*3/CYP2C19*3 (3/3).
DISCUSSION
The previous studies suggest a key role of the immune system in the development of ticlopidineinduced liver damage (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) . Few results from [11] [12] [13] [14] N/A N/A N/A past research suspected the contribution of cytochrome P450 enzyme system variability to drug-induced hepatotoxicity (28) (29) . The genetic polymorphism of certain cytochrome P450 enzymes lead to differences in actual drug metabolism. The evidence from published studies showed that "slow metabolizers" have increased susceptibility to drug-induced toxicity (11, (28) (29) . We aimed to investigate the role of cytochrome CYP2C 19 genetic polymorphism in the development of ticlopidineinduced cholestatic hepatitis and relate it to the specific immune reactivity and the inducement of necrosis and apoptosis as possible mechanisms of liver damage.
The results of our preliminary study indicate that the Th 1 type of immune responses were predominantly associated with ticlopidine-induced cholestatic hepatitis. The Th 1 type cytokines, especially IFN-y, were in the past related to the development of liver cell injury in hepatitis B virus transgenic mouse (30) . Similarly, intracellular cytokine staining (lCCS) of peripheral CD8+ T cells for IFN-y confirmed their role in liver damage (19) . The T cell proliferative responses to ticlopidine were positive among all patients with ticlopidineinduced cholestaic hepatitis. None of the individuals exposed in the past to ticlopidine (tic1opidine treated individuals without liver injury) showed proliferative responses to the drug. This finding was consistent with the results published by Skumik et al. (18) . On the same note, the gradual decrease in Thl type cytokines (lFN-y, IL-2 and TNF-a) and the inverse correlations between IFN-y and IL-10, IL-2 and IL-I0 and finally TNF-a and IL-IO serum levels during withdrawal period suggest that Thl type cytokine reactivity is predominant in patients with drug-induced liver damage. Although, cytokine serum levels do not exactly demonstrate
Ticlopidine specific T cell responses
Eur. J. Inllamm. this immunopathological process within the liver as, for example , ICCS of intrahepatic lymhocytes , they are able to indirectly confirm the role of Thl type cytokines in liver damage. The involvement of different cytokines gene polymorphisms was suggested to participate in the immunopathogenesis of drug-induced liver damage (31) .
TTAg and PHA specific T cell responses
The commentary from Woodward and Neuberger (32) explained why in Maria's study (20) there were no positive T cell proliferative responses among some patients with drug-induced liver damage . In contrast to this finding, all patients with ticlopidineinduced cholestatic hepatitis showed T cell proliferative responses to ticlopidine during all the withdrawal period without need of prostaglandine E inhibitor treatment (20) or presence of HepG2 cells (19) in the culture system. The genetic polymorphism of cytochrome CYP2C 19 gene might make clear this difference to the previously described results. The presence of the "slow metabolizers" genotypes (CYP2CI9*2 and CYP2CI9*3) among all ticlopidine-related cholestatic hepatitis patients indicates that cytochrome CYP2C 19 gene polymorphism is directly involved in the pathogenesis of ticlopidine-induced liver damage .
In contrast, any of ticlopidine treated individuals without liver damage did not have "slow metabolizer" cytochrome CYP2C 19 genotype . Ticlopidine acts as a selective mechanism -based inhibitor of human cytochrome P450 2C19 and the possibility of increased ticlopidine concentrations above therapeutical range in "slow metabolizers" due to cytochrome CYP2C 19 gene polymorphism might justify this discrepancy in T cell proliferation results. Unfortunately, we were not able to establish this hypothesis by the exact measurement of ticlopidine and its metabolites serum concentrations among ticlopidine-exposed patients in our study. The other justification of this dissimilarity could be due to the small number of cases studied of these relatively rare condition s.
The contribution of cytotoxic T lymphocytes in drug-induced liver damage was demonstrated previously (19) . The antigen-specific cytotoxic T lymphocytes contribute to the activation of Fas ligand (FasL) surface receptors and interact with FasL on the surfaces of natural killer (NK) cells or macrophages. This commencement triggers Fas-induced apoptosis cascade after activation of Fas-antigens (CD95+) on hepatocyte surfaces (33- 34). The immunohistochemistry results showed that the proportion of CD8+ cells in portal tracts as well as intralobular and Fas-antigen expression in hepatocytes were increased within the liver tissue of cholestatic hepatitis patients in contrast to healthy subjects. The serum concentrations of soluble markers of Fas-apoptosis, sFas and sFasL, were elevated among these patients. The positive correlation between the serum concentrations of soluble apoptosis markers and cytokine TNF-a ultimately indicates the association of this cytokine with apoptosis (33, 35) . This finding was supported by TUNEL assay results. The increased serum levels of TNF-a and soluble apoptosis markers in patients with obstructive cholestasis are constant with previously published findings (36) .
In conclusion, the results of the present study indicate that the gene polymorphism of cytochrome CYP2C19 is directly involved in the pathogenesis of ticlopidine-induced liver damage. The Thl type responses are related to the immunopathogenesis of liver damage and lead to the induction of liver cells necrosis and apoptosis. The data from our preliminary investigation support the previously suggested hypothesis of metabolic and immunological mechanism combination in the development of druginduced liver damage. Further research comprising results from a higher number of studied cases should confirm the theory.
